A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, Agarwal PK, Sosale A, Gandhi P, Dharmalingam M, Mohan V, Mahesh U, Kim DM, Kim YS, Kim JA, Kim PK, Baik SH.
Yang SJ, et al. Among authors: kim ja, kim dm, kim ys, kim pk.
Diabetes Obes Metab. 2013 May;15(5):410-6. doi: 10.1111/dom.12042. Epub 2012 Dec 17.
Diabetes Obes Metab. 2013.
PMID: 23170990
Clinical Trial.